TY - JOUR

T1 - A proposal for a study on treatment selection and lifestyle recommendations in chronic inflammatory diseases

T2 - A danish multidisciplinary collaboration on prognostic factors and personalised medicine

AU - Andersen, Vibeke

AU - Holmskov, Uffe

AU - Bek Sørensen, Signe

AU - Jawhara, Mohamad

AU - Andersen, Karina W.

AU - Bygum, Anette

AU - Hvid, Lone

AU - Grauslund, Jakob

AU - Wied, Jimmi

AU - Glerup, Henning

AU - Fredberg, Ulrich

AU - Villadsen, Jan Alexander

AU - Kjær, Søren Geill

AU - Fallingborg, Jan

AU - Moghadd, Seyed A.G.R.

AU - Knudsen, Torben

AU - Brodersen, Jacob

AU - Frøjk, Jesper

AU - Dahlerup, Jens F.

AU - Nielsen, Ole Haagen

AU - Christensen, Robin

AU - Bo Bojesen, Anders

AU - Sorensen, Grith Lykke

AU - Thiel, Steffen

AU - Færgeman, Nils J.

AU - Brandslund, Ivan

AU - Stensballe, Allan

AU - Schmidt, Erik Berg

AU - Franke, Andre

AU - Ellinghaus, David

AU - Rosenstiel, Philip

AU - Raes, Jeroen

AU - Heitmann, Berit

AU - Boye, Mette

AU - Nielsen, Charlotte Lindgaard

AU - Werner, Lars

AU - Kjeldsen, Jens

AU - Ellingsen, Torkell

PY - 2017/5

Y1 - 2017/5

N2 - Chronic inflammatory diseases (CIDs), including Crohn’s disease and ulcerative colitis (inflammatory bowel diseases, IBD), rheumatoid arthritis, psoriasis, psoriatic arthritis, spondyloarthritides, hidradenitis suppurativa, and immune-mediated uveitis, are treated with biologics targeting the pro-inflammatory molecule tumour necrosis factor-α (TNF) (i.e., TNF inhibitors). Approximately one-third of the patients do not respond to the treatment. Genetics and lifestyle may affect the treatment results. The aims of this multidisciplinary collaboration are to identify (1) molecular signatures of prognostic value to help tailor treatment decisions to an individual likely to initiate TNF inhibitor therapy, followed by (2) lifestyle factors that support achievement of optimised treatment outcome. This report describes the establishment of a cohort that aims to obtain this information. Clinical data including lifestyle and treatment response and biological specimens (blood, faeces, urine, and, in IBD patients, intestinal biopsies) are sampled prior to and while on TNF inhibitor therapy. Both hypothesis-driven and data-driven analyses will be performed according to pre-specified protocols including pathway analyses resulting from candidate gene expression analyses and global approaches (e.g., metabolomics, metagenomics, proteomics). The final purpose is to improve the lives of patients suffering from CIDs, by providing tools facilitating treatment selection and dietary recommendations likely to improve the clinical outcome.

AB - Chronic inflammatory diseases (CIDs), including Crohn’s disease and ulcerative colitis (inflammatory bowel diseases, IBD), rheumatoid arthritis, psoriasis, psoriatic arthritis, spondyloarthritides, hidradenitis suppurativa, and immune-mediated uveitis, are treated with biologics targeting the pro-inflammatory molecule tumour necrosis factor-α (TNF) (i.e., TNF inhibitors). Approximately one-third of the patients do not respond to the treatment. Genetics and lifestyle may affect the treatment results. The aims of this multidisciplinary collaboration are to identify (1) molecular signatures of prognostic value to help tailor treatment decisions to an individual likely to initiate TNF inhibitor therapy, followed by (2) lifestyle factors that support achievement of optimised treatment outcome. This report describes the establishment of a cohort that aims to obtain this information. Clinical data including lifestyle and treatment response and biological specimens (blood, faeces, urine, and, in IBD patients, intestinal biopsies) are sampled prior to and while on TNF inhibitor therapy. Both hypothesis-driven and data-driven analyses will be performed according to pre-specified protocols including pathway analyses resulting from candidate gene expression analyses and global approaches (e.g., metabolomics, metagenomics, proteomics). The final purpose is to improve the lives of patients suffering from CIDs, by providing tools facilitating treatment selection and dietary recommendations likely to improve the clinical outcome.

KW - Biomarker

KW - Exercise

KW - Food

KW - Molecular epidemiology

KW - Patient related outcome measures (PROMs)

KW - Personalized medicine

KW - Red meat

KW - Smoking

KW - Treatment outcome

KW - Western style diet (WSD)

U2 - 10.3390/nu9050499

DO - 10.3390/nu9050499

M3 - Journal article

C2 - 28505128

AN - SCOPUS:85019440395

VL - 9

JO - Nutrients

JF - Nutrients

SN - 2072-6643

IS - 5

M1 - 499

ER -